Implications of “not me” drugs for health systems: lessons from age related macular degeneration

BMJ 2012; 344 doi: (Published 1 May 2012)
Cite this as: BMJ 2012;344:e2941

Related articles

Research: Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study

Letter: The scientific community should lobby to be able to apply for drug licences

Editor's Choice: Avastin versus Lucentis

Feature: Why using Avastin for eye disease is so difficult

Editorial: Anti-vascular endothelial growth factor treatment for eye diseases

News: Novartis takes legal action over trusts’ advice to use bevacizumab for wet AMD

Research: Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study

Data supplement

Web Extra

Web Extra

Web Extra

See more

Feature: Cancer Care Team

Editorial: The safety of incretin based drugs

Practice: Should doctors prescribe cannabinoids?

Endgames: Treatment allocation in trials: cluster randomisation

This article has been cited by other articles: